Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Modafinil: A Double-Blind Multicentric Study

Modafinil: A Double-Blind Multicentric Study Summary Modafinil is a central putative alpha-1 postsynaptic agonist with vigilance-promoting properties. Fifty narcoleptics (33 male and 17 female) participated in a multicentric study aimed at assessing the effects of the compound on night sleep, feeling on awakening, excessive daytime sleepiness and cataplexy. Modafinil was administered in a double-blind cross-over design at a daily dosage of 300 mg versus placebo. The duration of the study was 12 weeks, including a 2-week “run in” period with placebo, a first 4-week treatment period with either modafinil or placebo, a 2-week wash-out period with placebo and a second 4-week treatment period with either placebo or modafinil. Daily evaluation was based on a sleep log, visual analog scales, a sleep questionnaire and a clinical global index. Sleep laboratory evaluation took place on nights 1, 28, 42 and 70. It included 1 night of polysomnography preceded by a questionnaire on therapeutic and side effects, and a maintenance of wakefulness test (MWT). Sleep logs did not show any modification of night sleep, but a reduction of daytime sleepiness and sleep. Feeling on awakening was not modified. An overall benefit was noted by physicians as well as by patients. MWT disclosed a positive effect of modafinil on excessive daytime sleepiness. Cataplexy was not modified. Modafinil, Alpha adrenergic agonist, Maintenance of wakefulness testing, Sleepiness, Cataplexy This content is only available as a PDF. © 1994 American Sleep Disorders Association and Sleep Research Society http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png SLEEP Oxford University Press

Modafinil: A Double-Blind Multicentric Study

Download PDF
6 pages

Loading next page...
 
/lp/oxford-university-press/modafinil-a-double-blind-multicentric-study-W3CArzYWVZ

References (13)

Publisher
Oxford University Press
Copyright
© 1994 American Sleep Disorders Association and Sleep Research Society
ISSN
0161-8105
eISSN
1550-9109
DOI
10.1093/sleep/17.suppl_8.S107
Publisher site
See Article on Publisher Site

Abstract

Summary Modafinil is a central putative alpha-1 postsynaptic agonist with vigilance-promoting properties. Fifty narcoleptics (33 male and 17 female) participated in a multicentric study aimed at assessing the effects of the compound on night sleep, feeling on awakening, excessive daytime sleepiness and cataplexy. Modafinil was administered in a double-blind cross-over design at a daily dosage of 300 mg versus placebo. The duration of the study was 12 weeks, including a 2-week “run in” period with placebo, a first 4-week treatment period with either modafinil or placebo, a 2-week wash-out period with placebo and a second 4-week treatment period with either placebo or modafinil. Daily evaluation was based on a sleep log, visual analog scales, a sleep questionnaire and a clinical global index. Sleep laboratory evaluation took place on nights 1, 28, 42 and 70. It included 1 night of polysomnography preceded by a questionnaire on therapeutic and side effects, and a maintenance of wakefulness test (MWT). Sleep logs did not show any modification of night sleep, but a reduction of daytime sleepiness and sleep. Feeling on awakening was not modified. An overall benefit was noted by physicians as well as by patients. MWT disclosed a positive effect of modafinil on excessive daytime sleepiness. Cataplexy was not modified. Modafinil, Alpha adrenergic agonist, Maintenance of wakefulness testing, Sleepiness, Cataplexy This content is only available as a PDF. © 1994 American Sleep Disorders Association and Sleep Research Society

Journal

SLEEP – Oxford University Press

Published: Dec 1, 1994

There are no references for this article.